Alto Neuroscience
ANRO
114 hedge funds and large institutions have $778M invested in Alto Neuroscience in 2026 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 39 increasing their positions, 28 reducing their positions, and 22 closing their positions.
173% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $749K
39% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 28
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
29% more capital invested
Capital invested by funds: $602M → $778M (+$175M)
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
4% more funds holding
Funds holding: 110 → 114 (+4)
0.01% less ownership
Funds ownership: 83.99% → 83.98% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$33.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$28.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.2M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$9.92M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$29.6M |
| 2 |
PA
Perceptive Advisors
New York
|
-$9.25M |
| 3 |
Jennison Associates
New York
|
-$8.69M |
| 4 |
Millennium Management
New York
|
-$6.1M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.33M |
ANRO Hedge Fund Activity: Q2 2026 in Review
114 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Alto Neuroscience (ANRO) for Q2 2026, worth a combined $778M — up 29% from $602M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ANRO positions and 22 closed out — a net gain of 5 holders — while 39 added to existing stakes and 28 trimmed.
The largest buyer was BlackRock, adding an estimated $33.6M. The largest seller was Vestal Point Capital, cutting an estimated $29.6M.
- 114 institutional investors held Alto Neuroscience (ANRO) as of Q2 2026, up from 110 in Q1 2026.
- Funds reported $778M of Alto Neuroscience stock for Q2 2026, up 29% quarter-over-quarter.
- 27 funds opened new Alto Neuroscience positions in Q2 2026 and 22 closed out, a net change of +5 holders.
- The largest Alto Neuroscience buyer in Q2 2026 was BlackRock, an estimated $33.6M added.
- The largest Alto Neuroscience seller in Q2 2026 was Vestal Point Capital, an estimated $29.6M sold.
Based on aggregated 13F filings for Q2 2026.